CJC-1295: Research on the Long-Acting GHRH Analogue and Its Role in Growth Hormone Axis Studies

Introduction: Engineering Stability into a GHRH Analogue

The growth hormone-releasing hormone (GHRH) axis is a central regulator of growth hormone secretion, body composition, and metabolic function. Native GHRH has a very short half-life in circulation — on the order of minutes — because it is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) and other proteases. This instability limits its utility as a research tool or therapeutic agent requiring sustained GH axis stimulation.

CJC-1295 was developed to address this limitation. It is a synthetic GHRH analogue modified with a drug affinity complex (DAC) technology that enables covalent binding to circulating albumin — the most abundant protein in plasma — dramatically extending its half-life from minutes to days. This pharmacokinetic engineering has made CJC-1295 a widely referenced compound in GH axis research, where sustained GHRH receptor activation is an experimental objective.

This article reviews the published research on CJC-1295, its structural pharmacology, and the available clinical data. All information is for research and educational purposes only.

Structure and Pharmacokinetic Engineering

CJC-1295 is a 30-amino acid analogue of GHRH(1-29), which is itself the biologically active N-terminal fragment of the 44-amino acid GHRH molecule. CJC-1295 incorporates four amino acid substitutions relative to native GHRH(1-29) that increase its resistance to DPP-IV cleavage, improving intrinsic stability. The defining pharmacokinetic modification, however, is the maleimidopropionic acid (MPA) group added at the C-terminus through a lysine residue — this reactive group forms a covalent bond with the cysteine-34 position of circulating serum albumin after injection.

Albumin binding via the DAC technology extends the effective half-life of CJC-1295 dramatically. Published human pharmacokinetic data report a half-life of approximately 6-8 days following subcutaneous injection, compared to the 7-minute half-life of native GHRH. This extended half-life enables once-weekly (or less frequent) dosing while maintaining continuous GHRH receptor occupancy.

CJC-1295 Without DAC (Mod GRF 1-29)

It is important to distinguish CJC-1295 (with DAC, albumin-binding) from the compound sometimes referred to as “CJC-1295 without DAC” or “Modified GRF 1-29” — a GHRH(1-29) analogue with the same four amino acid substitutions but without the albumin-binding modification. This latter compound has a shorter half-life measured in hours rather than days and produces more pulsatile GH release. Researchers and clinicians reviewing literature and product information should confirm which construct is being referenced, as the two have meaningfully different pharmacokinetic profiles and GH secretion patterns.

Mechanism: GHRH Receptor Activation and GH Axis Stimulation

CJC-1295 acts by binding to and activating GHRH receptors on somatotroph cells in the anterior pituitary. This activation promotes synthesis and secretion of growth hormone, which then acts on peripheral tissues either directly through GH receptors or indirectly through hepatic IGF-1 production.

The distinguishing feature of CJC-1295’s pharmacodynamics — relative to native GHRH or shorter-acting GHRH analogues — is that it produces a sustained elevation in GH secretion and downstream IGF-1 levels rather than the discrete GH pulses that characterize physiological GH secretion. This sustained pattern is pharmacologically distinct from the pulsatile secretion produced by compounds like sermorelin or modified GRF 1-29, and its implications for receptor desensitization, downstream signaling patterns, and clinical outcomes are a subject of ongoing research interest.

Published Clinical Data

CJC-1295 has a modest but meaningful published clinical evidence base derived from early-phase trials conducted in healthy adult volunteers. The foundational published study appeared in the Journal of Clinical Endocrinology & Metabolism in 2006 (Alba et al.), providing phase 1 pharmacokinetic and pharmacodynamic data in human subjects.

Pharmacokinetic Findings

The 2006 study established that CJC-1295 administered subcutaneously produced dose-dependent increases in circulating GH and IGF-1 levels in healthy adults. The half-life data confirmed the albumin-binding mechanism was functioning as designed, with sustained GH elevation lasting several days following a single dose.

GH and IGF-1 Elevation

Across multiple dose cohorts, CJC-1295 produced statistically significant and dose-dependent elevations in mean 24-hour GH concentrations and serum IGF-1 levels. IGF-1 elevations persisted for up to two weeks after single doses at higher dose levels, consistent with the compound’s extended pharmacokinetic profile.

Tolerability in Early Trials

The tolerability profile in this early-phase study was generally favorable, with injection site reactions as the most common adverse events. No serious adverse events attributable to the compound were reported in this study population. As with all early-phase data, this does not establish a definitive long-term safety profile.

Body Composition Research Context

The rationale for CJC-1295 research in body composition studies derives from the well-characterized effects of GH and IGF-1 on lean mass, fat mass, and metabolic rate. Growth hormone promotes lipolysis and lean tissue preservation, and IGF-1 has direct anabolic effects on skeletal muscle. Sustained GHRH receptor activation by CJC-1295 — producing chronic IGF-1 elevation — has been proposed as a research tool for studying these GH axis effects in a controlled, injectable format.

Published body composition data specifically attributable to CJC-1295 in human subjects is limited; most body composition evidence in the GH secretagogue space derives from studies of other GHRH analogues or GH itself. The compound’s body composition effects are largely inferred from its pharmacodynamic profile (sustained IGF-1 elevation) and analogy to established GH axis biology.

CJC-1295 in Combination Research: GHRH + GHRP

An important context for understanding CJC-1295 in the research community is its frequent investigation in combination with growth hormone-releasing peptides (GHRPs) such as ipamorelin, GHRP-2, or GHRP-6. GHRPs act through a distinct receptor (the ghrelin receptor / GHS-R1a) to synergistically amplify GH release when combined with GHRH receptor agonists.

The combination of a GHRH analogue (CJC-1295) and a GHRP (ipamorelin) is frequently discussed in the research and clinical literature as a strategy to produce greater GH secretion than either compound alone, while the GHRH component provides the permissive signal and the GHRP component amplifies the GH pulse. Published evidence for this synergistic mechanism exists primarily from studies of shorter-acting GHRH analogues plus GHRPs; the specific combination dynamics of the long-acting CJC-1295 with GHRPs are less extensively characterized in published trials.

Current Status

CJC-1295 does not hold FDA approval for any indication. It was developed by ConjuChem Biotechnologies and entered early clinical investigation, but did not advance to regulatory approval. It is referenced in research literature and available from research supply sources. Its use outside of registered clinical research settings is not within approved medical channels.

Researchers and clinicians reviewing publications should note that much of what is discussed about CJC-1295 in non-peer-reviewed contexts (forums, wellness communities) extrapolates from limited published clinical data and from the general pharmacology of the GH axis, rather than from large-scale controlled trials of the compound itself.

Summary

CJC-1295 is a pharmacokinetically engineered GHRH analogue whose defining characteristic is an extended half-life achieved through covalent albumin binding. Published early-phase clinical data confirm its ability to produce sustained GH and IGF-1 elevation in healthy adults. As a research tool for studying sustained GHRH receptor activation and GH axis biology, it offers a well-characterized pharmacokinetic profile. Its regulatory status remains investigational, and its body composition effects in human subjects are less rigorously characterized than its pharmacokinetic and pharmacodynamic properties.

All content on Peptide Research Blog is for educational and research purposes only. CJC-1295 is not approved for any clinical use. This content does not constitute medical advice.